CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma - Takeaway - MDSpire
From the Journals

CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma

Researchers at The University of Texas MD Anderson Cancer Center have identified CD40 overexpression as a potential prognostic biomarker for angioimmunoblastic T-cell lymphoma, a rare subtype of non-H...

Share

  • 1

    CD40 overexpression identified as a potential biomarker for AITL.

  • 2

    AITL arises from T follicular helper cells.

  • 3

    The study utilized single-cell RNA sequencing and immunofluorescence.

  • 4

    Neoplastic TFH cells may adopt a T follicular–regulatory program.

  • 5

    CD40 elevation may stratify patient risk and monitor treatment response.

  • 6

    Further research is needed on T follicular–regulatory phenotype frequency.

  • 7

    Future studies may explore CD40-targeted therapies.

Original Source(s)

CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma

  • by Wendy LaGrego

  • April 22, 2026

Related Content

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed...

First-Line Zongertinib in Advanced <em>HER2</em>-Mutant NSCLC

In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell...

Lung Cancer’s Hidden Layers

Study shows that tumor complexity can limit biopsy-based diagnosis

  • April 22, 2026

  • 2 min